null

null

null

null

null

null

null

null

null

null

null

null

null

null

0.02x Total Debt / Equity (Conservative)

Low direct sensitivity; debt-free with ~$300M+ cash runway, but rising rates increase opportunity cost and pressure biotech valuations via discount rate expansion

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) China-based API/intermediate chemical synthesis; 2) India-based contract manufacturing for peptide intermediates

Minimal international revenue currently; primary exposure via JNJ partnership milestones denominated in USD, limiting direct FX devaluation risk

Predominantly US-based operations; no material direct international revenue exposure; partnership royalties and milestones contracted in USD

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single CMO partners for rusfertide and imetelstat peptide synthesis; substitution would require 12-24 months regulatory revalidation

Clinical-stage biopharma; cloud disruption would cause operational delay but not existential risk; CRO/CMO dependencies are more critical chokepoints

Licensing and collaboration model with Johnson & Johnson (Janssen) as primary partner; milestone and royalty revenue supplemented by internal pipeline development

Low API coupling risk; uses standard SaaS tools for operations; core IP lock-in resides in proprietary peptide chemistry platform, not software integrations

Not applicable; equity securities in licensed biopharma; revenue model is milestone/royalty-based contracts, not investment contracts under Howey Test

Very High

Low-moderate; handles clinical trial patient data subject to GDPR (EU trials) and HIPAA; CCPA exposure limited given B2B/institutional data model

Low antitrust risk; niche rare hematology and oncology markets; no dominant market share; JNJ partnership unlikely to trigger monopolization concerns

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~100% transactional/milestone-based; upfront licensing fees, clinical/regulatory milestones, and future royalties; no recurring subscription revenue

Milestone payments plus tiered royalties on net sales from JNJ partnership; self-funded pipeline monetized via future licensing or commercialization

Royalty rates and milestone payments negotiated in partnership agreements; drug pricing ultimately set by JNJ for partnered assets, limiting Protagonist's direct pricing control

Moderate-high for novel peptide therapeutics in rare diseases with limited competition; orphan drug designations provide pricing leverage at commercialization

Expected 85-95% gross margin on royalty/milestone revenue; manufacturing COGS minimal for licensor; self-commercialized products may yield 70-80%

No free-rider problem; IP-protected platform; partnership agreements contractually binding; pipeline attrition (clinical failure) is the primary value leakage risk

Sublinear growth model; partnerships offload commercialization headcount to JNJ; internal R&D headcount scales modestly with pipeline expansion

Very low marginal cost for royalty/milestone revenue once drug approved; incremental pipeline assets require additional R&D spend but not proportional headcount

Not applicable; not a franchise business model

At 10x scale, JNJ handles commercial execution; Protagonist's CAC effectively embedded in R&D and partnering costs; partner acquisition cost per program ~$50-200M R&D

No meaningful network effects; value creation is IP and clinical data-driven; proprietary peptide chemistry platform creates competitive moat but not network dynamics

-19.4% Return on Assets (Negative equity)

High recession resistance; rare blood disorder treatments (PNH, polycythemia vera) are medically necessary; demand inelastic to economic cycles

Johnson & Johnson (Janssen) represents >80% of current revenues; extreme single-partner concentration risk for near-term financial performance

Future customers are specialty/rare disease patients and payers; commercial diversification dependent on rusfertide approval and potential self-commercialization strategy

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

3.5% CapEx / Revenue (Low-CapEx Asset-Light)

0001377121

PTGX